Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Sanofi-aventis

Hoescht Aktiengesellschaft

Sanofi

Guenter Mueller

Stefan Petry

Karl-Heinz Baringhaus

Rudolf Schneider

Karl Schoenafinger

Wendelin Frick

Eckhard Boles

Swen Hoelder

Silke Dlugai

Georg Tschank

Norbert Tennagels

Doerthe Voss

Hans Matter

David William Will

Matthias Urmann

Martin Bossart

Marc Korn

Siegfried Stengelin

Gerhard Jaehne

Hubert Heuer

Andreas W Herling

Michael R Myers

Reinhard Kirsch

Michael Kurz

Antony Bigot

Luigi Toti

Cordula Hopmann

Marcus Korn

Klaus-Peter Koller

Norbert Tennangels

Franz Jakob Hock

Roman Niedbal

The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

PIM-3 kinase as a target for type 2 diabetes mellitus

The invention relates to a strain of the yeastwhich, owing to deletion of the genomic sequences, no longer synthesizes hexose transporters and, as a consequence, can no longer grow on substrates with hexoses as the only carbon source, and whose ability of growing on a substrate with a hexose as the only carbon source is restored when it expresses a GLUT4 gene.

[object Object]

The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.

The present invention relates to a method for identification of a chemical compound which modulates the activity of mammalian GPI-PLC wherein a] a mammalian cell is incubated with glimepiride; b] hcDIGs of the cells of a] are prepared; c] the hcDIGs from b] are incubated with a chemical compound; d] the activity of the GPI-PLC from the hcDIGs of c] is determined.

Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation

Disclosed are compounds of the general formula (I), with the definitions of the substituents Rto R, A and X being detailed in the text, and to their physiologically tolerated salts, to processes for preparing these compounds and to the use thereof as inhibitors of hormone-sensitive lipase (HSL). 

Substituted N-aminomethylene sulfonamides, production and use thereof as medicaments

The invention therefore relates to compounds of the formula I in which the variables are as defined in the specification, to pharmaceutical compositions containing them and to their use for therapeutically lowering blood glucose levels.

Diphenylamine-substituted salicylthiazole derivatives and related compounds as phosphotyrosine phosphatase 1B (PTB1B) inhibitors for using as blood-sugar decreasing active ingredients for treating diabetes

The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diones, pharmaceutically acceptable salts thereof and physiologically functional derivatives. The invention therefore relates to compounds of the formula I, in which the radicals have the given meanings, and to their physiologically tolerated salts and processes for preparing them. The compounds are suitable for use as antidiabetics, for example.

Pyrimido[5,4-e][1,2,4]triazine-5-7-diones, processes for preparing them and their use

The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them consisting of the structure of formula I: Wherein R1, R2, A, B, D and E are defined herein. These 4-benzimidazol-2-ylpyridazin-3-ones and their derivatives and compositions comprising them are useful in the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase-3 &#x3b2; (GSK-3&#x3b2;) which is believed to cause the neurodegeneration that results in these diseases.

4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments

The present invention relates to pyridazinone compounds and their derivatives according to the general formula (I), with the substituents X, Rand Rdefined herein, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3&#x3b2; (glycogen synthase kinase-3&#x3b2;) which are useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome and syndrome X or immunodeficiency.

Pyridazinone derivatives, methods for their production and their use as pharmaceuticals

The invention refers to a protein from plasma membrane of adipocytes. The protein has specific binding affinity to phosphoinositoylglycans. It regulates glucose uptake by circumventing the insulin signaling cascade.

Phosophoinositoglycan binding proteins

The present invention relates to compounds according to the general formula (I) wherein X is selected from the group consisting of wherein n and p are independently 0, 1, 2, or 3, provided that n+p is a least 1; These compounds are useful for the manufacture of a medicament for the treatment of insulin resistance, type 2 diabetes, metabolic syndrome, lipid disorders or cardiovasular disease or for providing an anti-lipolytic effect.

Adenosine analogues and their use as pharmaceutical agents

Growing community of inventors

Sulzbach, Germany

Guenter Mueller